In melanoma and Merkel cell carcinoma, it has been shown that an increase of the frequency of PD-1+TIGIT+CD8+ circulating cells after one month of anti-PD-1 therapy was associated with OS and clinical response [174]. The gene discussed is CD8A; the disease is melanoma.